Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Cejas

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Vaccine|September 30, 2023
Evaluation of a stabilized RSV pre-fusion F mRNA vaccine: Preclinical studies and Phase 1 clinical testing in healthy adultsJesse Nussbaum, Xin Cao, Radha A Railkar, et al.
Cell Host & Microbe|December 8, 2021
Upper and lower respiratory tract correlates of protection against respiratory syncytial virus following vaccination of nonhuman primatesTomer Zohar, Jeff C Hsiao, Nickita Mehta, et al.
Immunity|June 25, 2013
Dendritic cell expression of the signaling molecule TRAF6 is critical for gut microbiota-dependent immune toleranceDaehee Han, Matthew C Walsh, Pedro J Cejas, et al.
JCI Insight|March 23, 2026
DNA delivered by lipid nanoparticles induces CD8+ T cell-dependent antitumor responses and enhances anti-PD-L1 therapySeoyun Yum, Alba Rodríguez-Garcia, Joan Castellsagué, et al.
Nature Communications|September 14, 2019
A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoproteinAimin Tang, Zhifeng Chen, Kara S Cox, et al.
NPJ Vaccines|March 5, 2020
Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infectionAmy S Espeseth, Pedro J Cejas, Michael P Citron, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Vaccine|September 30, 2023
Evaluation of a stabilized RSV pre-fusion F mRNA vaccine: Preclinical studies and Phase 1 clinical testing in healthy adultsJesse Nussbaum, Xin Cao, Radha A Railkar, et al.
Cell Host & Microbe|December 8, 2021
Upper and lower respiratory tract correlates of protection against respiratory syncytial virus following vaccination of nonhuman primatesTomer Zohar, Jeff C Hsiao, Nickita Mehta, et al.
Immunity|June 25, 2013
Dendritic cell expression of the signaling molecule TRAF6 is critical for gut microbiota-dependent immune toleranceDaehee Han, Matthew C Walsh, Pedro J Cejas, et al.
JCI Insight|March 23, 2026
DNA delivered by lipid nanoparticles induces CD8+ T cell-dependent antitumor responses and enhances anti-PD-L1 therapySeoyun Yum, Alba Rodríguez-Garcia, Joan Castellsagué, et al.
Nature Communications|September 14, 2019
A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoproteinAimin Tang, Zhifeng Chen, Kara S Cox, et al.
NPJ Vaccines|March 5, 2020
Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infectionAmy S Espeseth, Pedro J Cejas, Michael P Citron, et al.
Pageof 3